Company intelligence / Profile preview

Eggnovo

Spain

Ownership: Private
Development stage: Other

Overview

Eggnovo’s branded ingredients (Ovoderm, Ovomet, Ovopet, Ovocet) have been validated in over 20 in vitro, in vivo, and clinical studies, supporting their efficacy for joint, skin, bone, and general wellness applications in humans and animals[1].

Therapeutic areas: EndocrinologyDermatologyRheumatology
Modalities: ProteinBiologic
Industry: Non-Drug Biotech

Partnerships

IQI Trusted Petfood Ingredients (North American distribution partner for Ovopet)[3]

Beyond the preview

Go deeper on Eggnovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eggnovo.

Explore the full profile